Given these findings, the DHA–FFAR4 pathway offers potential for improving orthodontic treatments, particularly for patients prone to increased inflammation and reduced bone remodeling, such as those with age-related inflammatory disorders, obesity, or metabolic syndromes. This evidence concerns the gene FFAR4 and obesity disorder.